Perspectives on plasma biomarkers for point-of-care diagnostics in Alzheimer's disease: Insights into 2D-BioPAD
We investigated the potential of plasma biomarkers for point-of-care in vitro diagnostics in Alzheimer's disease by collecting insights from 99 stakeholders primarily from Greece, including patients, caregivers, healthcare professionals, and researchers. Data from an online survey was analyzed using descriptive statistics and thematic analysis. Key biomarkers reported by participants included Aβ 40 , Aβ 42 , pTau181, pTau217, and neurofilament light chain. While biomarkers were recognized for their value in prognosis, diagnosis, and monitoring, most participants were unfamiliar with point-of-care in vitro diagnostics. Major concerns regarding implementation included cost, reimbursement, and accessibility, underscoring the need for more feasible and context-appropriate diagnostic solutions.
Authors
- Anthoula Tsolaki (ORCID: https://orcid.org/0000-0002-5563-7776)
- Apostolos C. Tsolakis (ORCID: https://orcid.org/0000-0003-2606-1402)
- Angeliki Koukoura (ORCID: https://orcid.org/0000-0003-3295-8873)
- Gitte Juel Holst (ORCID: https://orcid.org/0009-0000-6627-3923)
- Kyriaki Antonopoulou (ORCID: https://orcid.org/0000-0002-9212-737X)
- Lutz Froelich (ORCID: https://orcid.org/0000-0003-1494-0813)
- Efstathios Vassiliadis (ORCID: https://orcid.org/0000-0001-6513-7903)
- Eirini Papadaki
- Alina Solomon
- Magda Tsolaki
Institutions
- University of Eastern Finland (FI)
- Heidelberg University (DE)
- Finland University (FI)
- Q PLAN International (Greece) (GR)
- Navitas Systems (United States) (US)
- Greek Association of Alzheimer's Disease and Related Disorders (GR)
- Heidelberg University (US)
Publication Details
- Journal
- Journal of Alzheimer s Disease Reports
- Published
- 2026-04-01
- DOI
- https://doi.org/10.1177/25424823261437790
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- HORIZON EUROPE Framework Programme